Literature DB >> 27585515

Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation.

Sally G Tamayo, Jason C Simeone, Beth L Nordstrom, Manesh R Patel, Zhong Yuan, Nicholas M Sicignano, W Frank Peacock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27585515     DOI： 10.1016/j.jacc.2016.06.028

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  3 in total

1.  Therapeutic duplication of anticoagulants: a retrospective study of frequency and consequences in a tertiary referral hospital.

Authors:  Ramin Rahmanzade; Francisco Cabrera Diaz; Claudia Zaugg; Philipp Schuetz; Ali Reza Salili
Journal:  Thromb J       Date:  2020-08-03

2.  Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.

Authors:  Shang-Hung Chang; I-Jun Chou; Yung-Hsin Yeh; Meng-Jiun Chiou; Ming-Shien Wen; Chi-Tai Kuo; Lai-Chu See; Chang-Fu Kuo
Journal:  JAMA       Date:  2017-10-03       Impact factor: 56.272

Review 3.  Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants.

Authors:  A John Camm; Keith A A Fox
Journal:  Open Heart       Date:  2018-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.